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Lysophosphatidic acid (LPA) is a lipid mediator which binds to G-protein-coupled receptors and regulates various cellular
responses, including inﬂammation of endothelial cells. Interleukin- (IL-) 1β, a proinﬂammatory cytokine, is elevated upon
LPA treatment in human umbilical vein endothelial cells (HUVECs). Previous studies indicated that LPA upregulates vascular
endothelial growth factor- (VEGF-) C and lymphatic marker expressions in HUVECs. However, the relationships between LPA-
inducedVEGF-CandIL-1β expressions are notclear. In thispaper, we demonstrated that, inthe presence ofAF12198, an inhibitor
of the IL-1 receptor abolished LPA-induced VEGF-C and lymphatic marker expressions in HUVECs. Furthermore, LPA-induced
in vitro tube formation of HUVECs was also suppressed by pretreatment with AF12198. Our results suggest that LPA-stimulated
lymphangiogenesis in HUVECs is mediated through IL-1β-induced VEGF-C expression.
1.Introduction
Lysophosphatidic acid (LPA) is a low-molecular-weight
lysophospholipid (LPL). Through binding to the endothe-
lial diﬀerentiation gene (Edg) family of G-protein-coupled
receptors (GPCRs), LPA regulates many cellular functions
[1–3]. In serum, LPA reaches micromolar concentrations
and accounts for much of the cellular growth eﬀects of
serum [1, 4]. The major sources of LPA are mainly activated
platelets, injured cells, and growth factors [5], and it can
also be secreted by multiple cell types, including ovarian
cancer cells [6]. LPA binds to at least ﬁve LPA receptors:
LPA1∼LPA5. Upon binding to these receptors, LPA regulates
multiple endothelial cell functions, including proliferation,
wound healing, and migration [7–13]. These results indicate
that LPA plays important roles in inﬂammation, wound
healing, and tumorigenesis [6].
Lymphangiogenesis, the process of growth and forma-
tion of new lymphatic vessels [14], occurs in normally
developing tissues and pathological processes, particularly
inﬂammation, wound healing, and cancer metastasis [15,
16]. Like angiogenesis, lymphangiogenesis is regulated by
various growth factors, cytokines, and hormones [17].
Among these regulators, vascular endothelial growth factor-
(VEGF-) C is considered to be a major regulator of the
lymphangiogenic process [18, 19]. In transgenic mouse
skin and mature chick chorioallantoic membrane models,
VEGF-C is known to induce both lymphangiogenesis and
angiogenesis [20, 21]. Several recent studies reported that
lymphatic vessels accumulate adjacent to tumor tissues
highly expressing VEGF-C, and an increase in the lymphatic
diameter may contribute to promotion of tumor metas-
tasis [22]. We demonstrated that LPA stimulates VEGF-
C and lymphatic markers, including Prox-1, LYVE-1, and
podoplanin expressions in human umbilical vein endothe-
lial cells (HUVECs) [23, 24]. In addition, sphingosine-1-
phosphate (S1P), another bioactive lysophospholipid, was
also demonstrated to induce lymphangiogenesis [25]. Those
results indicate that bioactive lipids may be important
lymphangiogenic regulators.2 International Journal of Inﬂammation
Despite studies suggesting connections between inﬂam-
mation and lymphangiogenesis, the molecular mechanisms
that regulate lymphatic vessel formation remain largely
unclear. Proinﬂammatory cytokines, such as interleukin-
(IL-) 1β and tumor necrosis factor- (TNF-) α, were shown
to enhance the expression of VEGF-C by ﬁbroblasts [26].
Moreover, IL-1β-induced lymphangiogenesis is mediated
through VEGFR-3 in the mouse cornea [27]. Those ﬁndings
suggest that cytokines are important mediators of lymphan-
giogenesis.
In our previous studies, we demonstrated that LPA
upregulates VEGF-C and lymphatic marker expressions in
HUVECs [23, 24]. Moreover, we also demonstrated that
LPA upregulates IL-1β messenger (m) RNA expression in
HUVECs [28]. In this study, we postulated that IL-1β,
the main proinﬂammatory cytokine, regulates LPA-induced
lymphangiogenesis in HUVECs. In this report, we showed
thatLPAupregulatedVEGF-Candlymphaticmarkerexpres-
sionsinHUVECsinLPA1/3-,EGFRtransactivation-,andIL-
1-dependent manners. Furthermore, we also demonstrated
that LPA-induced HUVEC tube formation in vitro was
suppressed by pretreatment with these inhibitors. These data
demonstrate for the ﬁrst time that IL-1β may act as an
essential mediator for LPA-induced lymphangiogenesis in
HUVECs.
2.MaterialandMethods
2.1. Reagents and Antibodies. Medium 199 and fetal bovine
serum (FBS) were purchased from HyClone (Logan, UT),
and endothelial growth medium (EGM) was purchased
from Cell Application (San Diego, CA). Trypsin-EDTA was
purchased from Gibco BRL (Grand Island, NY). Collagenase
I, gelatin, LPA, fatty acid-free bovine serum albumin (faf-
BSA), and Ki16425 were purchased from Sigma-Aldrich
(St. Louis, MO). Normal mouse and goat immunoglobulin
Gs (IgGs) were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). AG1478 and GM6001 were purchased
from Calbiochem (La Jolla, CA). Penicillin and streptomycin
were purchased from Invitrogen (Carlsbad, CA). AF12198
was purchased from Tocris (Ellisville, MO).
2.2. Cell Culture. Human umbilical cords were kindly pro-
vided by National Taiwan University Hospital (Institutional
Review Board approval no. 9561709146). HUVECs were
isolated from fresh umbilical cords by treatment with 0.1%
collagenase type I (Sigma) in cord buﬀer at 37
◦C for 30min.
Then endothelial cells (ECs) were collected and centrifuged.
HUVECs were cultured on 1% gelatin-coated (Sigma) 10cm
plates in 60% M199 medium supplemented with 100U/mL
penicillin, 100mg/mL streptomycin, 20% FBS, and 20%
EGM. Cells underwent one passage weekly. Cells were
subcultured after trypsinization and used in experiments
until passage 4.
2.3. Determination of IL-1β Protein Expression by an Enzyme-
Linked Immunosorbent Assay (ELISA). Starved HUVECs
were pretreated with an inhibitor for 1h, followed by LPA
(5μM) treatment for an additional 24h. The conditioned
medium was measured by an IL-1β ELISA kit purchased
from Cayman Chemical (Ann Arbor, MI).
2.4. Determination of VEGF-C Protein Expression by an
ELISA. Starved HUVECs were pretreated with an inhibitor
for 1h, followed by LPA (5μM) treatment for an additional
24h,andtheconditionedmediumwasmeasuredbyaVEGF-
C ELISA kit from R and D Systems (Minneapolis, MN).
2.5. CyFlow Analysis. HUVECs were starved for 16h and
treated as indicated. Suspensions of 106 cells in 200μL
phosphate-buﬀered saline (PBS) with 0.1% faf-BSA received
2μL of a rabbit antihuman Prox-1 antibody (Abcam, Cam-
bridge, MA), goat antihuman LYVE-1 (R & D Systems), or
mouse antihuman podoplanin (Santa Cruz Biotechnology)
andwerethenincubatedfor1hat4◦C.Antibody-conjugated
cells were washed with PBS three times and incubated
with an FITC-conjugated goat anti-rabbit secondary anti-
body (Molecular Probes, Eugene, OR), donkey anti-goat
secondary antibody (Molecular Probes), or goat anti-mouse
secondary antibody (DAKO, Carpentaria, CA) for 1h at 4◦C.
Fluorescent signals were determined by CyFlow SL (Partec,
M¨ unster, Germany) and analyzed by WinMDI version 2.8
software.
2.6. Matrigel Tube Formation Assay. Matrigel (BD Pharmin-
gen, San Diego, CA) at 0.3mL/well was plated evenly in a 24-
well plate, and incubated at 37
◦C for 30min before seeding
with HUVECs (5 × 104 cells/well). Tube formation was
studied for 6h, and photographs were taken. The original
magniﬁcation was 100x. The Matrigel was ﬁxed, blocked,
permeabilized, and stained with rabbit anti-mouse Prox-1
(Abcam), followed by incubation with a goat anti-rabbit
AlexaFluor-555-conjugated secondary antibody (Molecular
Probes). The Matrigel was thoroughly washed and incubated
with Mec13.3, a direct FITC-conjugated rat anti-mouse mAb
against PECAM-1 (BD Biosciences, San Jose, CA). After a
further series of washes with PBS, samples were mounted on
glass slides and viewed using a Zeiss ﬂuorescence microscope
(Oberkochen, Germany).
2.7. Statistical Analysis. All experiments were performed at
least three times, and the data are expressed as the mean ±
SD. An analysis of variance (ANOVA) was performed using
Statview 5.0 software. P<. 05 was considered statistically
signiﬁcant.
3. Results and Discussion
3.1. LPA-InducedLymphatic Marker Expressions Are Mediated
through EGFR Transactivation-, Matrix Metalloproteinase-
(MMP-), LPA1/3-, and IL-1R-Dependent Pathway in
HUVECs. O u rp r e v i o u ss t u d i e sd e m o n s t r a t e dt h a tL P A
enhances IL-1β mRNA expression in HUVECs [28], and
LPA induces the expressions of VEGF-C and lymphatic
markers in human endothelial cells [23]. In addition,
IL-1β stimulates VEGF-C expression in HUVECs [26].International Journal of Inﬂammation 3
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Figure 1: Lysophosphatidic acid- (LPA-) induced lymphatic marker expressions are mediated through endothelial growth factor receptor
(EGFR) transactivation-, matrix metalloproteinase- (MMP-), LPA1/3-, and interleukin- (IL-) 1R-dependent pathways in human umbilical
vein endothelial cells (HUVECs). Starved HUVECs were pretreated with AG1478 (100nM), AF12198 (10nM), GM6001 (10μM), Ki16425
(10μM), and toxin B (10nM) for 1h, followed by LPA (5μM) treatment for an additional 8h. HUVECs were dissociated by trypsinization
and ﬁxed with 4% paraformaldehyde. Fixed cells were labeled with antibodies for Prox-1, LYVE-1, and podoplanin, and then analyzed by
CyFlow. Cells were also stained with a normal mouse or goat immunoglobulin G antibody, which served as a negative control.
Therefore, we further investigated whether IL-1β plays
a role in LPA-induced lymphangiogenesis and whether
LPA1/3 or EGFR transactivation mediates LPA-induced
lymphangiogenesis in HUVECs. These enhancement eﬀects
were suppressed by pretreatment with inhibitors of LPA1/3
(Ki16425), EGFR kinase (AG1478), a broad-spectrum MMP
(GM6001), and IL-1R (AF12198). However, pretreatment
with a Rac inhibitor (toxin B) showed no suppressive eﬀects
(Figure 1). These results indicated that LPA’s enhancement
of Prox-1, LYVE-1, and podlymphaticmarker expressions
are oplanin protein expressions in HUVECs is mediated
by LPA1/3-, EGFR transactivation-, MMP-, and IL-1R-
dependent mechanisms.
3.2. LPA-Induced IL-1β Protein Expression Is Mediated
by EGFR Transactivation-, MMP-, LPA1/3-, and IL-1R-
Dependent Mechanisms in HUVECs. Since LPA-induced
lymphatic marker expressions are mediated by the IL-1R in
HUVECs (Figure 1), we further investigated whether LPA
stimulates IL-1β expression and whether LPA1/3 or EGFR
transactivation mediates LPA-induced IL-1β expression in
HUVECs. We observed that treatment with LPA (5μM) sig-
niﬁcantly enhanced IL-1β protein expression in HUVECs. In
addition, LPA-induced IL-1β protein expression in HUVECs
was blocked by Ki16425, AG1478, GM6001, and AF12198.
A Rac inhibitor (toxin B) showed no suppressive eﬀects
(Figure 2). These results indicate that the enhancement of
IL-1β protein expression by LPA in HUVECs is mediated
by LPA1/3-, EGFR transactivation-, MMP-, and IL-1R-
dependent mechanisms. Our previous study indicated that
LPA induced MMP activity and EGFR transactivation [13,
23, 24]. GM6001, a broad-spectrum MMP inhibitor, is
known to reduce LPA-induced EGFR transactivation. In this
study, we showed that GM6001 and AG1478 could inhibit
LPA-induced IL-1β expression. These results indicated that
LPA-induced IL-1β expression may act through EGFR
transactivation.
3.3. LPA-Stimulated VEGF-C Protein Expression Is Medi-
ated by EGFR Transactivation-, MMP-, LPA1/3-, and IL-
1R-Dependent Mechanisms in HUVECs. The present study
showed that IL-1β plays an important role in LPA-induced
lymphangiogenesis. Moreover, we demonstrated that VEGF-
C mediates LPA-induced lymphangiogenesis. Since both IL-
1β and VEGF-C mediate LPA-induced lymphangiogenesis,
we next investigated whether LPA-stimulated VEGF-C pro-
tein expression is mediated by an IL-1 receptor mechanism.
LPA-induced VEGF-C protein expression in HUVECs was
blocked by Ki16425, AG1478, GM6001, and AF12198.
Pretreatment with a Rac inhibitor (toxin B) showed no
suppressive eﬀects (Figure 3). These results indicate that
the enhancement of VEGF-C protein expression by LPA in
HUVECs is also mediated through these pathways.
3.4. LPA-Stimulated Endothelial Cell Tube Formation In Vitro
Is Mediated by EGFR Transactivation-, MMP-, LPA1/3-,
andIL-1R-DependentMechanisms. Tofurtherverifywhether
LPA1/3, EGFR transactivation, and IL-1β play critical roles












































































Figure 2: Lysophosphatidic acid- (LPA-) induced interleukin- (IL-)
1β protein expression is mediated through endothelial growth
factor receptor (EGFR) transactivation-, matrix metalloproteinase-
(MMP-), LPA1/3-, and IL-1R-dependent mechanisms in human
umbilical vein endothelial cells (HUVECs). Starved HUVECs were
pretreated with AG1478 (100nM), AF12198 (10nM), GM6001
(10μM),Ki16425 (10μM),and toxin B(10nM) for 1h,followed by
LPA (5μM) treatment for an additional 24h. Conditioned medium




∗∗P <. 01, and
∗∗∗P <. 001 indicate a
statistically signiﬁcant diﬀerence with the untreated control.
were pretreated with 100nM of AG1478, 10nM of AF12198,
10μM of GM6001, 10μM of Ki16425, or 10nM of toxin
Bf o r1 h ,f o l l o w e db yL P A( 5 μM) treatment for an addi-
tional 24h, and then Matrigel tube formation assays were
performed. After 6h of plating, Matrigel of each experiment
was ﬁxed and subjected to an immunocytochemical assay.
By immunostaining with PECAM-1, an endothelial cell
marker, expression levels were stimulated by LPA induction
a n dc o m p a r e dt ot h eu n t r e a t e dc o n t r o l( Figure 4). These
results further demonstrated that LPA-induced tube for-
mation in HUVECs is mediated through LPA1/3-, EGFR
transactivation-,andIL-1R-dependentmechanisms.Accord-
ing to immunostaining with Prox-1, we observed that LPA
upregulated the expression of Prox-1, a lymphatic marker.
These enhancement eﬀects were also suppressed by an
inhibitor of LPA1/3, EGFR kinase, a broad-spectrum MMP,
andIL-1R.However,aninhibitorofRac(toxinB)showedno
suppressive eﬀects (Figure 4). These results demonstrate that
LPA-induced tube formation and lymphatic marker expres-
sions are also mediated by LPA1/3-, EGFR transactivation-,
and IL-1R-dependent mechanisms.
A previous study indicated that basal mRNA expression















































































Figure 3: Lysophosphatidic acid- (LPA-) stimulated vascular
endothelial growth factor- (VEGF-) C protein expression is
mediated through endothelial growth factor receptor (EGFR)
transactivation-, matrix metalloproteinase- (MMP-), LPA1/3-, and
interleukin- (IL-) 1R-dependent mechanisms in human umbilical
vein endothelial cells (HUVECs). Starved HUVECs were pretreated
with AG1478 (100nM), AF12198 (10nM), GM6001 (10μM),
Ki16425 (10μM), and toxin B (10nM) for 1h, followed by LPA
(5μM) treatment for an additional 24h. Conditioned medium was
measured by an ELISA as described in “Methods”. All ELISA data
are expressed as the mean ± SD from at least three independent
experiments.
∗P <. 05,
∗∗P <. 01, and
∗∗∗P <. 001
indicate a statistically signiﬁcant diﬀerence with the untreated
control.
[29]. In addition, IL-3 induces the transformation of blood
endothelial cells (BECs) into lymphatic endothelial cells
(LECs). In this study, we also reported that LPA induced
lymphatic marker expressions in HUVECs. These ﬁndings
suggested that non-LECs can be used to study lymphan-
giogenesis. However, the eﬀects of LPA on adult LECs or
endothelial stem cells will be important experiments to carry
out.
Both inﬂammation and lymphangiogenesis are aggra-
vated by enhanced production of cytokines, chemokines,
growth factors, and lipid mediators. It was reported
that expressions of LPA-induced inﬂammatory response
genes are mediated through a nuclear factor- (NF-) κB-
dependent pathway [30]. Moreover, our data showed that
LPA induces lymphangiogenesis via an IL-1β-dependent
pathway. Accordingly, LPA acts as a regulator of both lym-
phangiogenesis and inﬂammation. Like LPA, S1P is known
to be a proinﬂammatory agent in the airway epithelium. In
addition, S1P also plays a role in regulating lymphatic vessel
maturation [31]. S1P1 is expressed in lymphocytes, and
S1P regulates migration of T-cells from nonlymphoid tissues
to the lymph [system?] [32]. Moreover, human lymphatic
ECs (HLECs) express S1P1 and S1P3, and S1P acts as aInternational Journal of Inﬂammation 5
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Figure 4: Lysophosphatidic acid- (LPA-) stimulated endothelial cell tube formation in vitro is mediated through endothelial growth factor
receptor (EGFR) transactivation-, matrix metalloproteinase- (MMP-), LPA1/3-, and interleukin- (IL-) 1R-dependent mechanisms. Starved
HUVECs were pretreated with AG1478 (100nM), AF12198 (10nM), GM6001 (10μM), Ki16425 (10μM), and toxin B (10nM) for 1h,
followedbyLPA(5μM)treatmentforanadditional24h,andthencellswereseededontoMatrigel-coatedplates.After6hofplating,Matrigel
of each experiment was ﬁxed and subjected to an immunocytochemical assay. The Matrigel was stained with PECAM-1 or a Prox-1 primary
antibody followed by an FITC-conjugated secondary antibody. Images were taken after plating and visualized by immunoﬂuorescence
microscopy.
lymphatic regulator [25]. These results further conﬁrm that
bioactive lipids may be regulators of both inﬂammation and
lymphangiogenesis.
The lymphatic vascular system has critical roles in
regulating interstitial pressure, homeostasis, and inﬂamma-
tion. Several studies suggested that new lymphatic vessel
formation can be caused by chronic inﬂammation. For
example, TNF-α, a proinﬂammatory factor, was found to be
a mediator driving blood vessel remodeling and lymphan-
giogenesis in inﬂammation [33]. VEGF-C is mainly derived
from inﬂammatory cells, which are involved in regulating
lymphangiogenesis via VEGFR-3 signaling in LECs [34].
Moreover, Prox-1 and podoplanin were shown to be induced
by inﬂammatory cytokines in diﬀerentiated ECs [29]. Those
results suggest that inﬂammation evokes the formation of



















Figure 5: Proposed mechanisms of lysophosphatidic acid- (LPA-) induced lymphangiogenesis in human endothelial cells.
Cytokines, such as TNF-α and IL-1β,w e r er e p o r t e d
to enhance VEGF-C expression in an NF-κB-dependent
mannerinHUVECs[26,33].Inaddition,IL-1β alsoinduced
lymphangiogenesis in mouse corneas through upregulating
the production of VEGF-C and VEGF-D [27]. Our previous
study demonstrated that LPA induced VEGF-C expres-
sion and lymphangiogenesis in human ECs. Furthermore,
LPA stimulated IL-8 and MCP-1 expressions via an IL-1-
dependent pathway [28]. In this study, we clariﬁed that the
LPA-induced lymphangiogenesis cascade acts through an IL-
1β-dependent pathway which is a crucial pathway involved
in the inﬂammatory response. This is consistent with a
previous study demonstrating that IL-1β plays a key role in
lymphangiogenesis [27].
As shown in Figure 2, we found LPA-induced IL-1β
protein expression in human ECs. However, the enhance-
ment eﬀects were abolished by treatment with AF12198, an
inhibitor of the IL-1 receptor, suggesting that the regulation
of IL-1 has a positive-feedback mechanism. Our results are
consistent with those of the Dinarello and Savage (1989)
study showing that IL-1 has a self-augmentation induction
mechanism, which allows a positive-feedback mechanism to
amplify the eﬀects of cytokines within the local environment
[35].
In summary, this study is the ﬁrst to establish that
IL-1β is necessary for LPA-induced VEGF-C expression
and lymphangiogenesis in human endothelial cells, which
suggests that both LPA and IL-1β may be potent targets
for generating therapeutics against lymphangiogenesis and
tumor metastasis.
4. Conclusions
Our data clearly indicate that LPA-induced VEGF-C expres-
sion is largely mediated by the IL-1 receptor. Further-
more,LPAstimulatedlymphaticmarkerexpressionsthrough
upregulating IL-1β protein expression in HUVECs, thereby
inducing the progression of lymphangiogenesis (Figure 5).
These ﬁndings suggest that LPA plays a critical role in
inﬂammation-induced lymphangiogenesis.
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